Special Report: Creso Pharmas first medical cannabis product has landed in Australia as the company sets itself up for 2020 as a truly global player in the industry.
Creso Pharmas (ASX:CPH) first shipment of its flagship medicinal cannabis product cannaQIX® 50 has arrived in Australia and is already being sold.
The medicinal cannabis product, sold under the brand name LozaCan via Burleigh Heads Cannabis distribution network, is already being prescribed and is receiving positive feedback from physicians and patients.
Creso Pharma and Burleigh Heads Cannabis are now exploring the potential to expand their collaboration to include more products from Creso Pharmas pipeline into the Australian market.
We are pleased to announce the first delivery of cannaQIX® 50 in Australia. Burleigh Heads Cannabis and CDA Clinics Australia continue to rapidly expand their patient reach with their extensive distribution network, Creso CEO and cofounder Dr Miri Halperin Wernli said.
This close partnership enables us to fulfil our mission of bringing life-improving products to patients in Australia. Were delighted to announce this progress and look forward to further new product introductions in the near future.
Swiss-made cannaQIX® 50 is Creso Pharmas proprietary buccally formulated cannabidiol (CBD) lozenge for chronic pain management.
Each lozenge contains 50mg of CBD and is designed to dissolve in the mouth in order to deliver the active ingredients more effectively into the bloodstream. By being dissolved in the mouth, the active ingredients enter the bloodstream directly, avoiding this first pass through the liver. cannaQIX 50 ® lozenges taste great and are a patient-friendly way to administer precise doses of CBD when compared to oil-based alternatives.
Creso Pharma has an exclusive distribution agreement with Burleigh Heads Cannabis, having secured an Australian import permit in April.
The collaboration will enable Creso Pharma to leverage Burleigh Heads Cannabis and its parent company CDA Healths local regulatory experience and established distribution
networks to facilitate patient access to its products in Australia.
We are delighted to mark this milestone in our collaboration with Creso Pharma. This collaboration will provide Australian patients and doctors with a quality product option to utilise for patient care, Burleigh Heads Cannabis managing director Guy Headley said.
By leveraging our experience with Australian regulations and established distribution networks, we believe that we will be able to deliver an innovative product option to benefit patients across Australia.
The post Creso Pharmas first Australian import has arrived and sales have already started appeared first on Stockhead.